Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers

被引:14
作者
Zhang, Di [1 ]
Huang, Qi-Fang [1 ]
Sheng, Chang-Sheng [1 ]
Li, Yan [1 ]
Wang, Ji-Guang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ctr Epidemiol Studies & Clin Trials, Shanghai Inst Hypertens, Ruijin Hosp,Sch Med, Ruijin 2nd Rd 197, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
Serum uric acid; antihypertensive therapy; clinic blood pressure; ambulatory blood pressure; dihydropyridine calcium channel blocker; HYPERTENSIVE PATIENTS; HYPERURICEMIA; KIDNEY; TRIAL; AMLODIPINE; GOUT;
D O I
10.1080/08037051.2021.1996220
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Purpose We investigated serum uric acid changes in relation to the achieved clinic and ambulatory blood pressure after 8 weeks of antihypertensive therapy with two dihydropyridine calcium channel blockers. Materials and methods The study participants were patients with clinic and ambulatory hypertension, enrolled in a randomised controlled trial that compared amlodipine (5-10 mg, n = 215) and nifedipine gastrointestinal therapeutic system (GITS, 30-60 mg, n = 203). Hyperuricaemia was defined as a serum uric acid concentration of >= 420 mu mol/L in men and >= 360 mu mol/L in women. Analysis of covariance and multiple regression analyses were performed to study the associations between serum uric acid changes and the achieved clinic and ambulatory blood pressure during follow-up. Results At baseline, 67 (16.0%) of the 418 patients had hyperuricaemia. Antihypertensive treatment reduced clinic and 24-h daytime and night-time systolic/diastolic blood pressure by a mean (+/- standard error [SE]) change of -17.4 +/- 0.6/-8.6 +/- 0.4 mm Hg and -13.7 +/- 0.5/-8.3 +/- 0.3 mm Hg, -13.8 +/- 0.6/-8.4 +/- 0.4 mm Hg, and -12.7 +/- 0.7/-8.0 +/- 0.4 mm Hg, respectively. Antihypertensive treatment reduced serum uric acid by a mean (+/- SE) change of -9.3 +/- 2.8 mu mol/L. The serum uric acid changes differed according to the achieved clinic and ambulatory blood pressure, and were statistically significant (mean +/- SE -20.6 +/- 6.6 to -10.7 +/- 2.9 mu mol/L, p <= 0.04) at the systolic/diastolic ranges of 130-139/>= 90 mm Hg in clinic pressure, and <130/75-84 mm Hg, <145/80-84 mm Hg and <120/65-69 mm Hg in 24-h, daytime and night-time ambulatory pressure. Conclusion Our study showed that antihypertensive therapy with a dihydropyridine calcium channel blocker was associated with reduced serum uric acid, especially when 24-h ambulatory systolic blood pressure was controlled.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 26 条
[1]   Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials [J].
Beddhu, Srinivasan ;
Greene, Tom ;
Boucher, Robert ;
Cushman, William C. ;
Wei, Guo ;
Stoddard, Gregory ;
Ix, Joachim H. ;
Chonchol, Michel ;
Kramer, Holly ;
Cheung, Alfred K. ;
Kimmel, Paul L. ;
Whelton, Paul K. ;
Chertow, Glenn M. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (07) :555-563
[2]   Drug-induced hyperuricaemia and gout [J].
Ben Salem, C. ;
Slim, Raoudha ;
Fathallah, Neila ;
Hmouda, Houssem .
RHEUMATOLOGY, 2017, 56 (05) :679-688
[3]   Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease [J].
Borghi, Claudio ;
Agabiti-Rosei, Enrico ;
Johnson, Richard J. ;
Kielstein, Jan T. ;
Lurbe, Empar ;
Mancia, Giuseppe ;
Redon, Josep ;
Stack, Austin G. ;
Tsioufis, Konstantinos P. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 80 :1-11
[4]   The Epidemiology and Genetics of Hyperuricemia and Gout across Major Racial Groups: A Literature Review and Population Genetics Secondary Database Analysis [J].
Butler, Faven ;
Alghubayshi, Ali ;
Roman, Youssef .
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (03)
[5]   Serum uric acid and arterial hypertension-Data from Sephar III survey [J].
Buzas, Roxana ;
Tautu, Oana-Florentina ;
Dorobantu, Maria ;
Ivan, Vlad ;
Lighezan, Daniel .
PLOS ONE, 2018, 13 (07)
[6]   Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016 [J].
Chen-Xu, Michael ;
Yokose, Chio ;
Rai, Sharan K. ;
Pillinger, Michael H. ;
Choi, Hyon K. .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (06) :991-999
[7]   CALCIUM-ANTAGONISTS AND THE KIDNEY - IMPLICATIONS FOR RENAL PROTECTION [J].
EPSTEIN, M .
AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (07) :S251-S259
[8]   Discovery and Development of Calcium Channel Blockers [J].
Godfraind, Theophile .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[9]   A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension [J].
Huang, Qi-Fang ;
Sheng, Chang-Sheng ;
Li, Yan ;
Dou, Yu ;
Zheng, Mei-Sheng ;
Zhu, Zhi-Ming ;
Wang, Ji-Guang .
JOURNAL OF CLINICAL HYPERTENSION, 2019, 21 (05) :648-657
[10]   The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study [J].
Ishimitsu, Toshihiko ;
Fukuda, Hirofumi ;
Uchida, Masako ;
Ishibashi, Kazushi ;
Sato, Fusako ;
Nukui, Kazuhiko ;
Nagao, Munehiko .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2015, 37 (07) :542-550